ClinicalTrials.gg
CompletedNCT05622864Updated Jul 24, 2025

Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients

A Phase 1 interventional study of HRS-9821 and HRS-9821 in Chronic Obstructive Pulmonary Disease, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 108 open to participants now, 125 under way, 15 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Enrollment
167th of 286
106 · median 155
Started
2023
with 44 others
Phase 1
28 of 404
4 open now
Registered
243rd of 404
by date

Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 167th largest by enrollment of the 286 interventional ones that give a count, is one of 45 that started in 2023, is one of 28 in phase 1, and was the 243rd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

108 of the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

103 more — sign in →

All 108 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

The increased safety and tolerance of single and multiple atomized inhalation of HRS-9821 suspension for inhalation doses in healthy subjects and COPD patients.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign an forms;
  2. Healthy men aged 18-50 (both ends, subject to the signing of the informed consent form); patients aged 40-75 (both ends, subject to the signing of the informed consent form);
  3. Weight ≥45 kg, 18-33 kg/m2 (include 33 kg/m2);
  4. During the screening period, the vital signs of healthy subjects are normal:

    • Shrinkage 90-140 mmHg,
    • diastolic pressure 50-90 mmHg,
    • Heart rate 40-100 times/min;
  5. During the screening period, the lung function of healthy subjects is normal, that is, the predicted value of ≥80% and the predicted value of FEV1/FVC≥92%; After COPD patients inhale bronchodilators, he predicted value of FEV1≥40% and the predicted value of FEV1/FVC\<0.7;
  6. During screening, the 12-lead is normal or abnormal but has no clinical significance.
  7. Follow the requirements within 14 weeks from the beginning of the consent to the last dose, and do not donate sperm during the consent period;
  8. During the study, all research regulations and procedures can be followed, and the atomization devices used by the research institute can be used correctly;
  9. Healthy subjects: non-smoking or quitting smoking ≥ 12 months, the previous smoking history \< 5 packs of years; COPD patients: the previous smoking history ≥ 10 packs of years.

Exclusion criteria

Exclusion Criteria:

  1. Healthy subjects: in the past 12 weeks, antibiotics have been used for upper and lower respiratory tract infections, or have a history of respiratory infections within the past 4 weeks; patients: in the past 4 weeks, antibiotics have been used for lower respiratory tract infections;
  2. Healthy subjects: abnormal laboratory or physical examination results of clinical significance;
  3. The average value of for 3 times at screening is ≥450ms;
  4. In the past four weeks, there have been blood donations or large blood loss (more than 400 milliliters), or those who intentionally donate blood during the study;
  5. Accept experimental drugs or use experimental medical devices within 1 months or less than 5 times the half-life of the drug, whichever is longer;
  6. In the past, there were difficulties in collecting blood or could not withstand intravenous puncture, such as needle halo and blood halo
  7. Any organ system has a history of malignant tumors;
  8. Known to be allergic to any accessories in the research drug or formulation;
  9. Previously known infection of (HIV), virus (HBV) liver or virus (HCV); or randomized pre-HIV (according to the test center SOP), treponema pallidum antibody (TPPA), HBV surface antigen or HCV antibody positive;
  10. There is a history of smoking and alcoholism in the 3 months before screening: smoking (more than 5 cigarettes or equivalent tobacco per day); alcoholism (more than 14 units of alcohol per week: 1 unit = 360 mL of beer, or 25 mL of spirits with a concentration of 40% or more, or 1 glass of wine, 180mL);
  11. In the past five years, there has been a history of drug abuse and drug dependence;
  12. Before randomization, positive for alcohol or drug abuse or nicotine in urine;
  13. During the study, there is a surgical plan or may interfere with the treatment plan carried out by the study;
  14. Inability or unwillingness to fully comply with the research program;
  15. Mentally or legally incapacitated;
  16. The researchers believe that there are any other reasons why the subjects are unfit to participate in the study;
  17. Prescription was used within 14 days before the first administration or within 48 hours before the first administration;
  18. Drugs that have used strong/intermediate inhibitors or induce liver drug metabolic enzyme 14 days before the first administration or ingest grapefruit or related products within 7 days before the first administration;
  19. During the study, it was expected to use drugs that had an effect on P-gp or breast cancer drug-resistant protein (BCRP).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Part A

    Drug: HRS-9821

  • Experimental
    Part B

    Drug: HRS-9821

Interventions

06

What researchers measure

Primary outcomes

  1. Assess the incidence and severity of adverse events after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: About a month from the first medication to the evaluation.

Secondary outcomes

  1. Evaluate the forced expiratory volume in one second (FEV1) after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: 2 hours after the first dose

  2. Evaluate the forced expiratory volume in one second (FEV1) after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: 4 hours after the first dose

  3. Evaluate the forced expiratory volume in one second (FEV1) after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: 6 hours after the first dose

  4. Evaluate the forced expiratory volume in one second (FEV1) after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: 12 hours after the first dose

  5. Evaluate the forced expiratory volume in one second (FEV1) after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: 24 hours after the first dose

  6. Evaluate the average value of FEV1 compared with baseline changes after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: 2 hours after the first dose

  7. Evaluate the average value of FEV1 compared with baseline changes after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: 3 hours after the first dose

  8. Evaluate the average value of FEV1 compared with baseline changes after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: 4 hours after the first dose

  9. Evaluate the average value of FEV1 compared with baseline changes after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: 12 hours after the first dose

  10. Evaluate the average value of FEV1 compared with baseline changes after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: 24 hours after the first dose

  11. Evaluate the change of FEV1 peak after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: About 24 hours after the first dose

  12. Evaluate the force lung capacity (FVC) after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: 2 hours after the first dose

  13. Evaluate pharmacokinetics concentration and pharmacokinetic parameters of after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.

    Time frame: 2 weeks after the first dose

07

Study locations

1 site
  • West China Hospital,Sichuan University
    Chengdu, Sichuan 610044, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in May 2025, 27 months.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 27 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2022
First posted
Nov 21, 2022
StartActual
Jan 12, 2023
Primary completionActual
May 7, 2025
CompletionActual
Jun 16, 2025
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05622864
Responsible party
Sponsor
First posted
Nov 21, 2022
Start date
Jan 12, 2023
Primary completion
May 7, 2025
Completion
Jun 16, 2025
Last update
Jul 24, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9821

Start the discussion